Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
AssigneeAbbott Laboratories
InventorsJoMay Chow, Steven R. Davis, Rachael Buck, Geralyn O. Duska-McEwen, Hawley K. Linke
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.
Claims19
A method of improving the feeding tolerance of an infant, toddler, or child, the method comprising administering to an infant, toddler, or child in need thereof a nutritional composition comprising at least one human milk oligosaccharide selected from the group consisting of 2′-fucosyllactose, lacto-N-neotetraose, and combinations thereof in a total amount of from about 0.001 mg/mL to about 20 mg/mL.
A method of improving the feeding tolerance of an infant, toddler, or child, the method comprising administering to an infant, toddler, or child in need thereof a nutritional composition comprising 2′-fucosyllactose and 6′-sialyllactose, wherein the 2′-fucosyllactose and 6′-sialyllactose are present in a total amount of from about 0.001 mg/mL to about 20 mg/mL.
A shelf stable synthetic formula for improving the feeding tolerance of an infant, toddler, or child, the synthetic formula comprising from about 0.001 mg/mL to about 20 mg/mL of an oligosaccharide blend, wherein the oligosaccharide blend comprises a first oligosaccharide, 2′-fucosyllactose, in a concentration of from 0.001 mg/mL to less than 2.0 mg/mL, and a second oligosaccharide, 6′-sialyllactose, in a concentration of from 0.001 mg/mL to less than 0.25 mg/mL.
Dependencies are inferred from the claim text.